Javascript must be enabled to continue!
Haemophilia Care in Martinique: From 1982 to 2015
View through CrossRef
Abstract
Introduction: Hemophilia A (HA) and B (HB) are the most common congenital bleeding disorders, characterised by missing clotting factor VIII (FVIII) for HA or factor IX (FIX) for HB, associated with specific mutations for the corresponding genes. This is the first article to focus on a localised specific hemophiliac population in the French West Indies.
Methods: Clinical, biological, genetic and socio-demographic data were collected at the Martinique Regional Centre for the Treatment of Hemophilia.
Results: Nowadays patients with hemophilia and von Willebrand diseases can benefit from clinical and paramedical care comparable to what prevails in mainland France. 130 hemophilia patients were diagnosed in Martinique. This study provides the first global report on epidemiological characteristics of hemophilia in Martinique. Hemophilia treatment center was established in 2000, implementation of care services, number and diagnoses of hemophilia patients, frequency of complications such as inhibitors, HIV and hepatitis C infection, and underlying genetic mutations are described.
Conclusion : These original data support that the French West Indies island of Martinique has the highest rate of HA and HB in the world compared to other countries. The establishment of a treatment center now provides standard of care to this population and may be a model for similar approaches in other French overseas regions.
Disclosures
No relevant conflicts of interest to declare.
American Society of Hematology
Title: Haemophilia Care in Martinique: From 1982 to 2015
Description:
Abstract
Introduction: Hemophilia A (HA) and B (HB) are the most common congenital bleeding disorders, characterised by missing clotting factor VIII (FVIII) for HA or factor IX (FIX) for HB, associated with specific mutations for the corresponding genes.
This is the first article to focus on a localised specific hemophiliac population in the French West Indies.
Methods: Clinical, biological, genetic and socio-demographic data were collected at the Martinique Regional Centre for the Treatment of Hemophilia.
Results: Nowadays patients with hemophilia and von Willebrand diseases can benefit from clinical and paramedical care comparable to what prevails in mainland France.
130 hemophilia patients were diagnosed in Martinique.
This study provides the first global report on epidemiological characteristics of hemophilia in Martinique.
Hemophilia treatment center was established in 2000, implementation of care services, number and diagnoses of hemophilia patients, frequency of complications such as inhibitors, HIV and hepatitis C infection, and underlying genetic mutations are described.
Conclusion : These original data support that the French West Indies island of Martinique has the highest rate of HA and HB in the world compared to other countries.
The establishment of a treatment center now provides standard of care to this population and may be a model for similar approaches in other French overseas regions.
Disclosures
No relevant conflicts of interest to declare.
Related Results
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
Haemophilia treatment in 2030
Haemophilia treatment in 2030
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
Bioclinical features of haemophilia patients in Benin in 2023: Towards better care
AbstractObjectiveTo analyse the demographic, clinical and laboratory data of Beninese patients with haemophilia.MethodA prospective survey was conducted in three different hospital...
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Sexual expression, fulfilment and haemophilia: reflections from the 16th Australian and New Zealand Haemophilia Conference
Summary. Following a presentation given at the 16th Australian and New Zealand Haemophilia Conference; Enjoying your sex life: Issues and solutions for men with physical impairmen...
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
Hemgenix as First Gene Therapy for Treatment of Haemophilia B
We know about haemophilia B is an inheritable bleeding complaint performing from missing or inadequate situations of blood clotting Factor IX, a protein demanded to produce blood c...
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Utilization of Fresh Frozen Plasma and Cryoprecipitate in Factor VIII and Factor IX Deficient Hemophilia Patient
Haemophilia is one of the most common causes of inherited bleeding disorder resulting from deficiency of coagulation factor VIII or factor IX. Ideally, replacement should be done w...

